Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma

Anticancer Res. 2017 Jun;37(6):3301-3306. doi: 10.21873/anticanres.11697.

Abstract

Background/aim: The goal of this retrospective study was to investigate the efficacy and safety of neoadjuvant chemoradiotherapy (CRT) in patients with Stage II or Stage III esophageal squamous cell carcinoma (SCC).

Patients and methods: Between January 2004 and December 2014, a total of 86 patients underwent surgical resection in conjunction with preoperative CRT for esophageal SCC in our Institute.

Results: A pathological complete response was achieved in 38.7% of patients with Stage II cancer and 20% of patients with Stage III. Postoperative complications were observed in 61.3% of Stage II and 76.4% of Stage III patients. The 5-year overall survival rate (OS) was 83.2% in Stage II and 22.8% in Stage III (p=0.0001). The 5-year disease-free survival (DFS) rate was 67.9% in Stage II and 29.9% in Stage III (p=0.0007).

Conclusion: Neoadjuvant CRT may improve OS and DFS rates in patients with Stage II esophageal SCC.

Keywords: Esophageal cancer; chemoradiotherapy; prognosis; stage II or III patients.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy*
  • Chemoradiotherapy, Adjuvant* / adverse effects
  • Chemoradiotherapy, Adjuvant* / mortality
  • Disease-Free Survival
  • Esophageal Neoplasms / mortality
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / therapy*
  • Esophageal Squamous Cell Carcinoma
  • Esophagectomy* / adverse effects
  • Esophagectomy* / mortality
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lymph Node Excision
  • Male
  • Middle Aged
  • Neoadjuvant Therapy* / adverse effects
  • Neoadjuvant Therapy* / mortality
  • Neoplasm Staging
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome